度普利尤单抗治疗成人结节性痒疹的疗效及安全性分析

Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis

目的:评估临床实践中度普利尤单抗治疗成人结节性痒疹(PN)的临床疗效与安全性。方法:回顾性分析2021年5月至2022年10月在昆明医科大学第二附属医院皮肤科接受度普利尤单抗规律治疗16周成人PN患者的临床及实验室资料。在0、4、8、16周使用瘙痒数字评分量表(NRS),皮肤病生活质量指数(DLQI),研究者总体评估(IGA)评分,湿疹面积和严重程度指数(EASI)对患者的临床症状和瘙痒情况进行评分,评估其疗效及安全性。结果:共纳入28例患者,第16周时,28例患者NRS、DLQI、IGA、EASI评分均出现显著下降,NRS、DLQI、IGA、EASI评分由基线时8.96±0.88、24.54±3.12、4.00±0.67、39.64±10.89分别降至0.96±0.88、2.43±1.40、0.86±0.53、7.10±3.68,差异均有统计学意义(均P<0.05)。1例患者出现眼干、4例患者出现局部注射反应,未报告其他不良事件。结论:度普利尤单抗可持续改善结节性痒疹的皮损和瘙痒情况,且安全性高,可作为结节性痒疹治疗新选择。

Objective:To evaluate the efficacy and safety of dupilumab in the treatment of adult prurigo nodularis(PN).Methods:The data of adult patients with PN who were treated with regular dupilumab for 16 weeks in our hospital from May 2021 to October 2021 were retrospectively anlyzed.The efficacy and safety were accessed using the Numerical rating scale(NRS),Dermatology Life Quality Index(DLQI),Investigator's Global Assessment(IGA),and Eczema area and severity index(EASI)at weeks 0,4,8,16.Results:A total of 28 patients were collected.After 16 weeks of treatment,the scores of NRS,DLQI,IGA and EASI of 28 patients all decreased significantly,which decreased from 8.96±0.88,24.54±3.12,4.00±0.67 and 39.64±10.89 at baseline to 0.96±0.88,2.43±1.40,0.86±0.53 and 7.10±3.68,respectively,with significant differences(Ps<0.05).Dry eye occurred in 1 patient,local injection reactions occurred in 4 patients,and no other serious adverse events occurred.Conclusion:Dupilumab can continuously improve the skin lesions and pruritus of nodular pruritus with high safety,which provide a new treatment option for PN.